Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 16 points (-0.1%) at 16,836 as of Monday, June 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,605 issues advancing vs. 1,347 declining with 197 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is unchanged. Top gainers within the industry include

Abbott Laboratories

(

ABT

), up 0.8%, and

Humana

(

HUM

), up 0.5%. On the negative front, top decliners within the industry include

Accelerate Diagnostics

(

AXDX

), down 16.4%,

ResMed

(

RMD

), down 4.0%,

Edwards Lifesciences

(

EW

), down 1.7%,

Fresenius Medical Care AG & Co. KGaA

(

FMS

), down 1.1% and

Varian Medical Systems

(

VAR

), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Smith & Nephew

(

SNN

) is one of the companies pushing the Health Services industry higher today. As of noon trading, Smith & Nephew is up $0.58 (0.7%) to $89.23 on light volume. Thus far, 92,765 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 248,300 shares. The stock has ranged in price between $88.86-$89.51 after having opened the day at $88.92 as compared to the previous trading day's close of $88.65.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $15.8 billion and is part of the health care sector. Shares are up 23.6% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Smith & Nephew a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Smith & Nephew

TheStreet Recommends

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Smith & Nephew Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Covance

(

CVD

) is up $2.21 (2.6%) to $85.95 on average volume. Thus far, 217,953 shares of Covance exchanged hands as compared to its average daily volume of 566,200 shares. The stock has ranged in price between $83.89-$86.16 after having opened the day at $84.58 as compared to the previous trading day's close of $83.74.

Covance Inc., a drug development services company, provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries worldwide. It operates in two segments, Early Development and Late-Stage Development. Covance has a market cap of $4.9 billion and is part of the health care sector. Shares are down 4.9% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Covance a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Covance

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, growth in earnings per share and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Covance Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Laboratory Corp of America Hldgs

(

LH

) is up $0.72 (0.7%) to $102.44 on average volume. Thus far, 521,374 shares of Laboratory Corp of America Hldgs exchanged hands as compared to its average daily volume of 909,200 shares. The stock has ranged in price between $101.47-$102.84 after having opened the day at $101.48 as compared to the previous trading day's close of $101.72.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. Laboratory Corp of America Hldgs has a market cap of $8.5 billion and is part of the health care sector. Shares are up 11.3% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Laboratory Corp of America Hldgs a buy, 2 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Laboratory Corp of America Hldgs

as a

buy

. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Laboratory Corp of America Hldgs Ratings Report

now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health services industry could consider

ProShares Ultra Short Health Care

(

RXD

).

null